Therapeutic Response

MSI-H status confers therapeutic sensitivity to Dostarlimab in patients with Endometrial Carcinoma.

Statements

Source and description
Jemperli (dostarlimab) [product monograph]. HC. Health Canada approved dostarlimab as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum containing regimen.